Results 291 to 300 of about 20,692 (311)

Dupilumab for recalcitrant Kimura disease

Dermatologic Therapy, 2022
Dupilumab for recalcitrant Kimura ...
Francesco Bellinato, Maria Gaia Mastrosimini, Giulia Querzoli, Paolo Gisondi, Giampiero Girolomoni   +4 more
openaire   +2 more sources

Dupilumab and alopecia: A Janus effect

Dermatologic Therapy, 2019
Atopic dermatitis (AD) and alopecia areata (AA) are two common skin diseases that can coexist in the same patient, sharing some pathogenetic mechanisms such as the overexpression of interleukin 4 (IL4) and interleukin 13 (IL13). Recently, cases of AA healing during treatment with anti-IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported ...
Patruno C., Napolitano M., Ferrillo M., Fabbrocini G.   +3 more
openaire   +4 more sources

New Indication for Dupilumab

AJN, American Journal of Nursing, 2022
Dupilumab (Dupixent) has been approved to treat eosinophilic esophagitis in adults and children ages 12 years and older who weigh at least 40 kilograms. This is the first drug approved to treat this disease.
openaire   +2 more sources

Dupilumab in Atopic Dermatitis

Current Treatment Options in Allergy, 2019
Atopic dermatitis (AD) is a common chronic inflammatory relapsing skin disease that greatly affects the quality of life of patients and their relatives. Topical treatment represents the initial therapeutic option in AD, although in patients with severe AD that do not respond to first-line topical therapies treatment with systemic immunosuppressive ...
Aída Gómez-Cardeñosa, Milagros Lázaro-Sastre, Asunción García-Sánchez, Ignacio Dávila   +3 more
openaire   +2 more sources

▼Dupilumab for atopic dermatitis

Drug and Therapeutics Bulletin, 2018
▼Dupilumab (Dupixent - Sanofi-Aventis Groupe), a monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis in adults who require systemic therapy, was licensed by the European Medicines Agency in September 2017. It is the first biological drug approved specifically for this condition.
openaire   +2 more sources

Dupilumab‐induced Urticaria

Dermatologic Therapy, 2021
Mastorino L., Ortoncelli M., Virginia B., Rolla G., Avallone G., Cavaliere G., Riccardo V., Quaglino P., Ribero S.   +8 more
openaire   +4 more sources

Dupilumab treatment of trichothiodystrophy in a child

Pediatric Dermatology
AbstractTrichothiodystrophy (TTD) is a rare congenital disorder caused by genetic mutations, leading to hair and skin abnormalities. We report successful treatment of a TTD case using dupilumab, a monoclonal antibody targeting IL‐4Rα. The patient, a 7‐year‐old boy, exhibited significant improvement in skin and hair conditions, suggesting the potential ...
Elisabetta Magnaterra, Mattia Giovannini, Cesare Filippeschi, Fausto Andrea Pedaci, Greta Tronconi, Michele Callea, Silvia Ricci, Francesca Mori, Maria Parpagnoli, Teresa Oranges   +9 more
openaire   +2 more sources

Dupilumab in Persistent Asthma

New England Journal of Medicine, 2013
Omer Kalayci, Ozlem Cavkaytar, Ebru Arik Yilmaz   +2 more
openaire   +7 more sources

Crisaborole, Dupilumab, and Sarilumab

Journal of the American Pharmacists Association, 2017
Daniel A. Hussar, Yunju Faith Lee
openaire   +3 more sources

Dupilumab for atopic dermatitis

The Lancet, 2017
Lindsay C. Strowd, Steven R. Feldman
openaire   +3 more sources